AGM/EGMApr 28, 2026, 05:07 PM
XLO 2026 Annual Meeting: Director Election, Stock Plan Approval
AI Summary
Xilio Therapeutics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled virtually for June 10, 2026. Stockholders will vote on the election of four Class II directors, the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026, and the approval of the Amended and Restated 2021 Stock Incentive Plan. The board also intends to rebalance its class structure following the election.
Key Highlights
- Xilio Therapeutics to hold 2026 Annual Meeting on June 10, 2026, virtually.
- Stockholders to vote on election of four Class II directors for 3-year terms.
- Proposal to ratify Ernst & Young LLP as independent auditor for FY2026.
- Proposal to approve Amended and Restated 2021 Stock Incentive Plan.
- Board plans to rebalance classes, appointing one Class II director to Class III.
- Record date for voting is April 16, 2026, with 5,982,839 shares outstanding.
- All share amounts adjusted for 1-for-14 reverse stock split on March 13, 2026.
Price Impact
More from XLO